title: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, the Center for Study of the Tumor Microenvironment, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Jaime R
authors.initials: JR
authors.lastname: Merchan
authors.forename: Deepa R
authors.initials: DR
authors.lastname: Jayaram
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Supko
authors.forename: Xiaoying
authors.initials: X
authors.lastname: He
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Bubley
authors.forename: Vikas P
authors.initials: VP
authors.lastname: Sukhatme
mesh_terms: D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000378:metabolism* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068579:Celecoxib; D003094:Collagen / Q000378:metabolism; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D007797:Laminin / Q000378:metabolism; D008168:Lung / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000098:blood supply / Q000188:drug therapy; D008565:Membrane Proteins; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D017239:Paclitaxel / Q000378:metabolism* / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy; D011509:Proteoglycans / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D012867:Skin / Q000187:drug effects; D012878:Skin Neoplasms / Q000098:blood supply / Q000188:drug therapy; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014471:Umbilical Veins / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004338:Drug Combinations; D007527:Isoenzymes; D007797:Laminin; D008565:Membrane Proteins; D011509:Proteoglycans; D011720:Pyrazoles; D013449:Sulfonamides; C059485:matrigel; D003094:Collagen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D017239:Paclitaxel